Navigation Links
Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
Date:3/30/2009

for heart failure and need for repeat vascularization. Strikingly, this analysis found a significant association between injected cell volume and improvement in ejection fraction that is suggestive of a dose effect. This summation of prior studies supports Amorcyte's subsequent prospective findings.

"Having successfully confirmed a dose effect, Amorcyte looks forward to proceeding with a larger prospective randomized trial and furthering our clinical program with AMR-001," said Andrew Pecora, M.D., Chairman of the Board of Amorcyte. "These strong Phase I results, combined with proprietary innovative technologies that address the challenges of commercializing stem cell products, position us to bring to market a stem cell therapy with the potential to address a serious unmet patient need."

About Cardiovascular Disease

It is estimated that each year there are approximately 1.1 million instances of acute myocardial infarction (AMI). 160,000 AMIs are severe enough to cause ventricular remodeling leading to further tissue damage over time and downstream adverse events including premature death, recurrent myocardial infarction, congestive heart failure, significant arrhythmias and acute coronary syndrome. Amorcyte's therapy aims to limit ventricular remodeling.

About Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell Therapy, a leading provider of clinical, manufacturing and ot
'/>"/>

SOURCE Amorcyte, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
2. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
6. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
7. Neogen Reports Record Third Quarter
8. Transgenomic, Inc. Reports Fourth Quarter and Fiscal Year 2008 Results
9. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
10. BMP Sunstone Reports Fourth Quarter and Full Year 2008 Financial Results
11. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
(Date:8/21/2014)... , Aug. 21, 2014  Decision Resources ... Brazil and Mexico ... uptake of several newly approved agents, the anticipated ... indication and the launch of emerging biologics will ... In particular, the emerging IL-5 inhibitors will introduce ...
(Date:8/21/2014)... , Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... plan to release financial results for the first quarter ... after market close in the US.  ... a.m. ET on Friday, August 29, 2014 to discuss ... the Company,s recent developments, followed by a question and ...
(Date:8/21/2014)... 2014 Ontotext S4 , The ... Ontotext . Now the same enterprise hardened text ... and unstructured data is available to start-ups and mid-size ... technology. Organizations that do not have resources to evaluate ... use S4 since there is no need for on ...
Breaking Biology Technology:His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
... Direct, a wholly owned subsidiary of Medco Health Solutions, ... provider of guidance and decision support for genomic medicine, ... Atlantic Health of Morristown, New Jersey, Crittenton Hospital Medical ... Chicago, Illinois, have joined the Genomic Medicine Network to ...
... 31, 2011 Caliper Life Sciences, Inc. (Nasdaq: ... agreed to a long-term, exclusive arrangement under which Caliper will ... North America. With the LabChip DS, an ... analyze the concentration levels of up to 96 nucleic acid ...
... Plus is pleased to offer Clinical and Non-Clinical ... health care organizations for front line selection and ... increase patient satisfaction and employee engagement and reduce turnover ... diminished medical errors and infection rates, better team dynamics, ...
Cached Biology Technology:Four Community Hospitals Join DNA Direct's Genomic Medicine Network 2Four Community Hospitals Join DNA Direct's Genomic Medicine Network 3Caliper Life Sciences Launches Microfluidic LabChip® DS Platform for UV/VIS Spectral Analysis of Nucleic Acid and Protein Samples 2Caliper Life Sciences Launches Microfluidic LabChip® DS Platform for UV/VIS Spectral Analysis of Nucleic Acid and Protein Samples 3Talent Plus' Health Care Talent Online® Assessments 2Talent Plus' Health Care Talent Online® Assessments 3
(Date:8/21/2014)... National University (ANU) team has successfully replicated one of ... biological systems powered by sunlight which could manufacture hydrogen ... is sunlight. It is an exciting prospect to use ... safely," said Dr Kastoori Hingorani, from the ARC Centre ... School of Biology. , Hydrogen offers potential as a ...
(Date:8/21/2014)... pancreatitis involves the pancreas digesting itself resulting in severe ... the UK around 20,000 patients are diagnosed with the ... cure and treatment is restricted to intravenous fluid and ... Faculty of Life Sciences, who led the research, said ... from gall stones and excessive alcohol intake combined with ...
(Date:8/20/2014)... In a study of 158 pregnant teenagers in Rochester, ... and intentional consumption of ice, cornstarch, vacuum dust, baby ... new Cornell study. , Moreover, such teens had significantly ... not eat nonfood substances. , Pregnant teens, regardless of ... can lead to iron deficiency and anemia. Low iron ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2Insulin offers new hope for the treatment of acute pancreatitis 2Pica in pregnant teens linked to low iron 2
... of Soil, they're just clever Lab guys. A team from ... Science Magazine with a new way to count bugs in ... our feet. , "Computational Improvements Reveal Great Bacterial Diversity and ... and John Dunbar, of Los Alamos' Bioscience Division, describes a ...
... CropScience and DuPont have developed two new classes of ... more effective way to fight pest insects that damage ... compounds designed to activate a novel insecticide target called ... problem of insecticide resistance, the researchers say. They described ...
... at The Schepens Eye Research Institute have discovered that ... in the eye and other parts of the body ... body's immune response and protect delicate tissues that cannot ... believe that this discovery may ultimately help in the ...
Cached Biology News:Using computers and DNA to count bacteria 2Novel compounds show promise as safer, more potent insecticides 2A protein in the eye may prevent immune response and protect eyes from disease 2
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
Biology Products: